Literature DB >> 7212167

Comparative efficacies of quinine and chloroquine as companions to primaquine in a curative drug regimen.

L H Schmidt.   

Abstract

A comparison has been made of the capacities of chloroquine and quinine to serve as companions to primaquine in curing established infections with sporozoites of the M or B strains of Plasmodium cynomolgi in rhesus monkeys. The results indicated that chloroquine was slightly but consistently more effective than quinine in this role. This finding provides support for use of chloroquine as the companion blood schizonticide in the current experimental animal-based search for improved tissue schizonticidal drugs, and bolsters the rather tenuous base for clinical use of this 4-aminoquinoline, rather than quinine, as a companion to primaquine in suppressive-curative and radical-curative regimens.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7212167     DOI： 10.4269/ajtmh.1981.30.20

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  10 in total

1.  Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.

Authors:  Gregory A Deye; Montip Gettayacamin; Pranee Hansukjariya; Rawiwan Im-erbsin; Jetsumon Sattabongkot; Yarrow Rothstein; Louis Macareo; Susan Fracisco; Kent Bennett; Alan J Magill; Colin Ohrt
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

3.  Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Therapeutic responses to different antimalarial drugs in vivax malaria.

Authors:  S Pukrittayakamee; A Chantra; J A Simpson; S Vanijanonta; R Clemens; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 5.  Artemisinin combination therapy for vivax malaria.

Authors:  Nicholas M Douglas; Nicholas M Anstey; Brian J Angus; Francois Nosten; Ric N Price
Journal:  Lancet Infect Dis       Date:  2010-06       Impact factor: 25.071

6.  Antimalarial activities and subacute toxicity of RC-12, a 4-amino-substituted pyrocatechol.

Authors:  L H Schmidt; R N Rossan; R Fradkin; R Sullivan; W Schulemann; L Kratz
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Enhancement of the curative activity of primaquine by concomitant administration of mirincamycin.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

8.  Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia Ex Vivo: Potentials and Pitfalls.

Authors:  Dominique Mazier; Georges Snounou; Laurent Dembélé; Jean-François Franetich; Valérie Soulard; Nadia Amanzougaghene; Shahin Tajeri; Teun Bousema; Geert-Jan van Gemert; Roger Le Grand; Nathalie Dereuddre-Bosquet; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 9.  Anti-malarial drug effects on parasite dynamics in vivax malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2021-03-21       Impact factor: 2.979

10.  Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.

Authors:  Steven P Maher; Amélie Vantaux; Victor Chaumeau; Adeline C Y Chua; Caitlin A Cooper; Chiara Andolina; Julie Péneau; Mélanie Rouillier; Zaira Rizopoulos; Sivchheng Phal; Eakpor Piv; Chantrea Vong; Sreyvouch Phen; Chansophea Chhin; Baura Tat; Sivkeng Ouk; Bros Doeurk; Saorin Kim; Sangrawee Suriyakan; Praphan Kittiphanakun; Nana Akua Awuku; Amy J Conway; Rays H Y Jiang; Bruce Russell; Pablo Bifani; Brice Campo; François Nosten; Benoît Witkowski; Dennis E Kyle
Journal:  Sci Rep       Date:  2021-10-07       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.